株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
企業レポート

PharmaPoint:関節リウマチ - 現在・将来の市場参入企業

PharmaPoint: Rheumatoid Arthritis - Current and Future Players

発行 GlobalData 商品コード 263599
出版日 ページ情報 英文 79 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
PharmaPoint:関節リウマチ - 現在・将来の市場参入企業 PharmaPoint: Rheumatoid Arthritis - Current and Future Players
出版日: 2014年12月31日 ページ情報: 英文 79 Pages
概要

当レポートでは、世界の関節リウマチ関連市場における既存企業および新規参入企業について分析し、市場全体の将来展望や促進・抑制要因、現在・将来の競争動向、主要企業のプロファイル(企業概要、事業展開、財務状況、SWOT分析)、市場全体と各企業の将来展望などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進・阻害要因:世界市場の課題

第4章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • AbbVie
    • Pfizer
    • Amgen
    • Johnson & Johnson
    • Eli Lilly
    • Bristol-Myers Squibb
    • UCB
    • Roche
    • GlaxoSmithKline
    • Novartis
    • Sanofi
    • AstraZeneca- MedImmune
    • アステラス製薬
    • Vertex
    • 第一三共

第5章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC1041FPR

GlobalData has released its pharma report, "PharmaPoint: Rheumatoid Arthritis - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Rheumatoid Arthritis Market. The report identifies and analyses the key companies shaping and driving the global Rheumatoid Arthritis market. The report provides insight into the competitive Rheumatoid Arthritis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Rheumatoid Arthritis
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of Rheumatoid Arthritis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving Rheumatoid Arthritis market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Rheumatoid Arthritis market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents

1 Table of Contents 8

  • 1.1 List of Tables 10
  • 1.2 List of Figures 11

2 Introduction 12

  • 2.1 Catalyst 12
  • 2.2 Related Reports 13
  • 2.3 Upcoming Related Reports 16

3 Market Outlook 17

  • 3.1 Global Markets 17
    • 3.1.1 Forecast 17
    • 3.1.2 Drivers and Barriers - Global Issues 22

4 Current and Future Players 25

  • 4.1 Trends in Corporate Strategy 28
  • 4.2 Company Profiles 29
    • 4.2.1 AbbVie 29
    • 4.2.2 Pfizer 31
    • 4.2.3 Amgen 34
    • 4.2.4 Johnson & Johnson 37
    • 4.2.5 Eli Lilly 39
    • 4.2.6 Bristol-Myers Squibb 41
    • 4.2.7 UCB 43
    • 4.2.8 Roche 45
    • 4.2.9 GlaxoSmithKline 47
    • 4.2.10 Novartis 49
    • 4.2.11 Sanofi 51
    • 4.2.12 AstraZeneca- MedImmune 53
    • 4.2.13 Astellas 55
    • 4.2.14 Vertex 57
    • 4.2.15 Daiichi Sankyo 59

5 Appendix 62

  • 5.1 Bibliography 62
  • 5.2 Abbreviations 67
  • 5.3 Methodology 70
  • 5.4 Forecasting Methodology 70
    • 5.4.1 Diagnosed RA Patients 70
    • 5.4.2 Percentage of Drug-Treated Patients 71
    • 5.4.3 General Pricing Assumptions 71
    • 5.4.4 Generic and Biosimilar Erosion 73
  • 5.5 Primary Research - KOLs Interviewed for This Report 73
  • 5.6 Primary Research - Prescriber Survey 75
  • 5.7 About the Authors 76
    • 5.7.1 Analyst 76
    • 5.7.2 Reviewer 76
    • 5.7.3 Therapy Area Director 77
    • 5.7.4 Global Head of Healthcare 77
  • 5.8 About GlobalData 78
  • 5.9 Disclaimer 78

List of Tables

1.1 List of Tables

  • Table 1: Global Sales Forecasts ($m) for RA, 2013-2023 19
  • Table 2: Global RA Market - Drivers and Barriers, 2013-2023 22
  • Table 3: Key Companies in the RA Market, 2014 27
  • Table 4: AbbVie's RA Portfolio Assessment, 2014 30
  • Table 5: Pfizers's RA Portfolio Assessment, 2014 33
  • Table 6: Amgen's RA Portfolio Assessment, 2014 36
  • Table 7: J&J's RA Portfolio Assessment, 2014 38
  • Table 8: Eli Lilly's RA Portfolio Assessment, 2014 40
  • Table 9: BMS' RA Portfolio Assessment, 2014 42
  • Table 10: UCB's RA Portfolio Assessment, 2014 44
  • Table 11: Roche's RA Portfolio Assessment, 2014 46
  • Table 12: GSK's RA Portfolio Assessment, 2014 48
  • Table 13: Novartis' RA Portfolio Assessment, 2014 50
  • Table 14: Sanofi's RA Portfolio Assessment, 2014 52
  • Table 15: AstraZeneca -MedImmune's RA Portfolio Assessment, 2014 54
  • Table 16: Astellas's RA Portfolio Assessment, 2014 56
  • Table 17: Vertex's RA Portfolio Assessment, 2014 58
  • Table 18: Daiichi Sankyo's RA Portfolio Assessment, 2014 60
  • Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 75

List of Figures

1.2 List of Figures

  • Figure 1: Global Sales for RA by Region, 2013-2023 21
  • Figure 2: Company Portfolio Gap Analysis in RA, 2013-2023 28
  • Figure 3: AbbVie SWOT Analysis in RA, 2013-2023 31
  • Figure 4: Pfizer SWOT Analysis in RA, 2013-2023 34
  • Figure 5: Amgen SWOT Analysis in RA, 2013-2023 36
  • Figure 6: J&J SWOT Analysis in RA, 2013-2023 39
  • Figure 7: Eli Lilly SWOT Analysis in RA, 2013-2023 41
  • Figure 8: BMS SWOT Analysis in RA, 2013-2023 43
  • Figure 9: UCB SWOT Analysis in RA, 2013-2023 45
  • Figure 10: Roche SWOT Analysis in RA, 2013-2023 47
  • Figure 11: GSK SWOT Analysis in RA, 2013-2023 49
  • Figure 12: Novartis SWOT Analysis in RA, 2013-2023 51
  • Figure 13: Sanofi SWOT Analysis in RA, 2013-2023 53
  • Figure 14: AstraZeneca/MedImmune SWOT Analysis in RA, 2013-2023 55
  • Figure 15: Astellas SWOT Analysis in RA, 2013-2023 57
  • Figure 16: Vertex SWOT Analysis in RA, 2013-2023 59
  • Figure 17: Daiichi Sankyo SWOT Analysis in RA, 2013-2023 61
Back to Top